Milestone Pharmaceuticals provides details on RESET-PSVT trial

Milestone Pharmaceuticals (MIST) announced details on RESET-PSVT, a planned Phase 4, multicenter, prospective, observational registry intended to generate real-world evidence on the use of Cardamyst nasal spray in adults with paroxysmal supraventricular tachycardia. “Registry of Etripamil Studies Evaluating Treatment in Paroxysmal Supraventricular Tachycardia: Study Design,” was presented in a poster session at the Preventive Cardiovascular Nurses Association Cardiovascular Nursing Symposium in Scottsdale, Arizona. The study will be led by the Duke Clinical Research Institute. RESET-PSVT is expected to enroll an estimated 450 adult patients across approximately 20 electrophysiology and cardiology sites, with enrollment beginning by the end of 2026. The registry is designed to evaluate patients who have been prescribed Cardamyst as well as patients prescribed or given other therapies, with enrolled patients and their healthcare providers completing patient- and provider-outcome surveys, respectively. The study’s primary endpoint is to characterize patterns of use of Cardamyst in PSVT management, including frequency of PSVT episodes, frequency of use of Cardamyst, number of doses administered per episode and triggers for use. Secondary endpoints include comparisons between Cardamyst and non-Cardamyst users across patient-reported quality of life, healthcare utilization and episode characteristics. Exploratory analyses are expected to evaluate prescribing and use patterns across patient subgroups, along with qualitative analysis of participant experience.